Please login to the form below

Not currently logged in


This page shows the latest CXA-201 news and features for those working in and with pharma, biotech and healthcare.

Cubist publishes positive data on novel antibiotic

Cubist publishes positive data on novel antibiotic

combination CXA-201 (ceftolozane/tazobactam) for complicated urinary tract and intra-abdominal infections in the US in April. ... CXA-201 is also due to be filed in Europe later this year and is in phase III testing for hospital-acquired bacterial

Latest news

  • Cubist posts positive phase III antibiotic data Cubist posts positive phase III antibiotic data

    CXA-201 combines a novel cephalosporin (ceftolozane) with a well-established beta-lactamase inhibitor and is designed to tackle Gram-negative bacterial infections. ... Data from the latest study demonstrated that CXA-201 was within 10 per cent of

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...